<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157959</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-104</org_study_id>
    <nct_id>NCT04157959</nct_id>
  </id_info>
  <brief_title>The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia</brief_title>
  <official_title>A Phase I, Single-Center, Open-Label Study to Evaluate Pharmacodynamics of Drug-Drug Interaction Between SHR4640 and Febuxostat in Patients With Hyperuricemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the pharmacodynamic properties of drug-drug of
      SHR4640 and Febuxostat interaction in patients with Hyperuricemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of SHR4640 and Febuxostat from plasma</measure>
    <time_frame>Day1 to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of SHR4640 and Febuxostat from plasma</measure>
    <time_frame>Day1 to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t1/2) of SHR4640 and Febuxostat from plasma</measure>
    <time_frame>Day1 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events</measure>
    <time_frame>Clinical significant changes from Day-21 up to Day 29</time_frame>
    <description>Laboratory indicators, 12-lead electrocardiogram (ECG), physical examination,vital signs, adverse events (NCI-CTC AE 5.0), etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>SHR4640</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR4640 dose1 Oral Tablet Day1~Day14 qd,Febuxostat dose2 Oral Tablet Day8 and Day14 qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat dose2 Oral Tablet Day1 and Day14 qd, SHR4640 dose1 Oral Tablet Day8~Day14 qd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640 dose1</intervention_name>
    <description>Tablet,dose1,QD</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_label>SHR4640</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat dose2</intervention_name>
    <description>Tablet,dose2,QD</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_label>SHR4640</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has a body mass index ≥18 and ≤30 kg/m2;

          2. Screening sUA value ≥8mg/dl;

          3. Subject has no clinically relevant abnormalities in vital signs, ECG, physical
             examination，imaging examination or safety laboratory values.

        Exclusion Criteria:

          1. Subject known or suspected of being sensitive to the study drugs or its ingredient；

          2. ALT、AST、TBIL&gt;ULN;

          3. History of kidney stones or screening kidney stones by B-ultrasound；

          4. History of malignancy；

          5. History of xanthinuria；

          6. Donated blood（≥400ml）within 3 months prior to screening or received transfusion of
             blood。
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cao Yu</last_name>
    <phone>0532-82911767</phone>
    <email>Caoyu1767@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Hospital of QingDao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shan Dong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cao Yu</last_name>
      <phone>0532-82911767</phone>
      <email>Caoyu1767@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

